Pfizer (PFE)

42.89 +0.13 (0.30%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/19 *Est.)

Latest Headlines

Form 11-K PFIZER INC For: Dec 31 June 17, 2019 2:35 PM - SEC Filing Form 11-K PFIZER INC For: Dec 31 June 17, 2019 2:12 PM - SEC Filing Form 11-K PFIZER INC For: Dec 31 June 17, 2019 2:09 PM - SEC Filing Pfizer (PFE) calls active on Array BioPharma (ARRY) deal June 17, 2019 9:56 AM - StreetInsider Form 8-K PFIZER INC For: Jun 14 June 17, 2019 7:13 AM - SEC Filing Pfizer to Acquire Array BioPharma June 17, 2019 6:54 AM - PR NewsWire Pfizer (PFE) June calls active into acquirng Array BioPharma (ARRY) June 17, 2019 6:53 AM - StreetInsider Pfizer (PFE) to Acquire Array BioPharma (ARRY) in $11.4 Billion Deal, $48/Share June 17, 2019 6:45 AM - StreetInsider Pfizer to Acquire Array BioPharma June 17, 2019 6:45 AM - BizWire Pfizer (PFE) Announces Results from XELJANZ XR ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with JAK Inhibitor June 12, 2019 8:02 AM - StreetInsider Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor June 12, 2019 8:00 AM - BizWire Sarepta Therapeutics (SRPT) option implied volatility increases into data June 10, 2019 11:01 AM - StreetInsider Sarepta Therapeutics (SRPT) June weekly option implied volatility bid June 7, 2019 10:52 AM - StreetInsider Sarepta Therapeutics (SRPT) July IV bid June 6, 2019 5:23 AM - StreetInsider Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development June 5, 2019 1:30 PM - BizWire Sarepta Therapeutics (SRPT) July option implied volatility elevated into data June 5, 2019 9:59 AM - StreetInsider Sarepta Therapeutics (SRPT) Volatility Likely Around PF-06939926 (DMD) Data on 6/28 - Morgan Stanley June 5, 2019 9:31 AM - StreetInsider Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer June 5, 2019 7:06 AM - StreetInsider Morgan Stanley Resumes Pfizer (PFE) at Overweight, Sees Growth Acceleration on Horizon June 4, 2019 7:40 AM - StreetInsider Form 4 PFIZER INC For: May 31 Filed by: JOHNSON RADY A June 3, 2019 9:36 PM - SEC Filing Form 4 PFIZER INC For: May 31 Filed by: ROGERS DAWN June 3, 2019 9:36 PM - SEC Filing Form 4 PFIZER INC For: May 31 Filed by: YOUNG JOHN D June 3, 2019 9:36 PM - SEC Filing Form 4 PFIZER INC For: May 31 Filed by: BOURLA ALBERT June 3, 2019 9:36 PM - SEC Filing Matinas BioPharma to Present at the 9th Annual LD Micro Invitational June 3, 2019 8:06 AM - StreetInsider Matinas BioPharma to Present at the 9th Annual LD Micro Invitational June 3, 2019 8:05 AM - Globe NewsWire Goldman Sachs Starts Pfizer (PFE) at Conviction Buy May 28, 2019 2:45 AM - StreetInsider Pfizer (PFE) Phase 3 Trial of LYRICA in PGTC Seizures Did Not Meet its Primary Endpoint May 24, 2019 4:01 PM - StreetInsider Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures May 24, 2019 4:00 PM - BizWire Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research May 21, 2019 8:00 AM - BizWire Form 4 PFIZER INC For: May 15 Filed by: YOUNG JOHN D May 17, 2019 3:50 PM - SEC Filing Form 4 PFIZER INC For: May 15 Filed by: ROGERS DAWN May 17, 2019 3:50 PM - SEC Filing Form 4 PFIZER INC For: May 15 Filed by: BOURLA ALBERT May 17, 2019 3:50 PM - SEC Filing Form 4 PFIZER INC For: May 15 Filed by: JOHNSON RADY A May 17, 2019 3:50 PM - SEC Filing Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting May 15, 2019 5:01 PM - BizWire Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates May 15, 2019 7:02 AM - StreetInsider Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates May 15, 2019 7:00 AM - Globe NewsWire Pfizer (PFE) Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib in Patients Aged 12 and Older with Moderate to Severe AD May 15, 2019 6:46 AM - StreetInsider Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis May 15, 2019 6:45 AM - BizWire FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma May 14, 2019 7:44 PM - PR NewsWire Form 10-Q PFIZER INC For: Mar 31 May 9, 2019 4:18 PM - SEC Filing Pfizer (PFE) PT Lowered to $44 at BMO Capital May 8, 2019 9:04 AM - StreetInsider Pfizer (PFE) Acquires Therachon for $340M Upfront, $470M Contingent May 8, 2019 6:46 AM - StreetInsider Pfizer Acquires Clinical-Stage Biotech Therachon May 8, 2019 6:45 AM - BizWire Pfizer (PFE) Announces EC Approves LORVIQUA for Certain Adult Patients with Previously-Treated ALK-Positive Advanced NSCLC May 7, 2019 7:10 AM - StreetInsider European Commission Approves LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer May 7, 2019 7:00 AM - BizWire GlycoMimetics, Inc. Announces Enrollment Completed for Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease May 6, 2019 9:00 AM - BizWire Pfizer (PFE) PT Raised to $48 at Credit Suisse May 6, 2019 8:43 AM - StreetInsider Pfizer (PFE) Announces U.S. FDA Approves VYNDAQEL and VYNDAMAX for Use in Patients with Transthyretin Amyloid Cardiomyopathy May 6, 2019 6:47 AM - StreetInsider U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease May 6, 2019 6:45 AM - BizWire Form 4 PFIZER INC For: Apr 30 Filed by: YOUNG JOHN D May 1, 2019 3:48 PM - SEC Filing Form 4 PFIZER INC For: Apr 30 Filed by: JOHNSON RADY A May 1, 2019 3:48 PM - SEC Filing Form 4 PFIZER INC For: Apr 30 Filed by: BOURLA ALBERT May 1, 2019 3:48 PM - SEC Filing Form 4 PFIZER INC For: Apr 29 Filed by: ROGERS DAWN May 1, 2019 3:48 PM - SEC Filing Pfizer (PFE) PT Raised to $43 at Wolfe Research May 1, 2019 8:45 AM - StreetInsider Form 8-K PFIZER INC For: Apr 30 April 30, 2019 8:59 AM - SEC Filing Pfizer (PFE) Tops Q1 EPS by 10c; Bumps EPS Outlook April 30, 2019 6:46 AM - StreetInsider PFIZER REPORTS FIRST-QUARTER 2019 RESULTS April 30, 2019 6:45 AM - BizWire Form 8-K PFIZER INC For: Apr 25 April 29, 2019 4:53 PM - SEC Filing ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV April 29, 2019 7:06 AM - BizWire Form 4 PFIZER INC For: Apr 25 Filed by: KILTS JAMES M April 26, 2019 5:33 PM - SEC Filing Form 4 PFIZER INC For: Apr 25 Filed by: LITTMAN DAN R. April 26, 2019 5:33 PM - SEC Filing Form 4 PFIZER INC For: Apr 25 Filed by: SMITH JAMES C April 26, 2019 5:33 PM - SEC Filing Form 4 PFIZER INC For: Apr 25 Filed by: NORA JOHNSON SUZANNE M April 26, 2019 5:33 PM - SEC Filing Form 4 PFIZER INC For: Apr 25 Filed by: NARAYEN SHANTANU April 26, 2019 5:33 PM - SEC Filing Form 4 PFIZER INC For: Apr 25 Filed by: Echevarria Joseph April 26, 2019 5:32 PM - SEC Filing Form 4 PFIZER INC For: Apr 25 Filed by: HOBBS HELEN April 26, 2019 5:32 PM - SEC Filing Form 4 PFIZER INC For: Apr 25 Filed by: BLAYLOCK RONALD E April 26, 2019 5:32 PM - SEC Filing Pfizer (PFE) Receives Positive CHMP Opinion for TALZENNA April 26, 2019 11:03 AM - StreetInsider Pfizer Receives Positive CHMP Opinion for TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer April 26, 2019 11:00 AM - BizWire Pfizer Hosts Annual Meeting of Shareholders April 25, 2019 11:17 AM - BizWire Pfizer (PFE) PT Lowered to $43 at UBS April 22, 2019 6:59 AM - StreetInsider Pfizer (PFE). Eli Lilly & Co. (NYSE:LLY) Report Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis April 18, 2019 5:06 PM - StreetInsider Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis April 18, 2019 5:05 PM - BizWire Pfizer Invites Public to Listen to Webcast of April 25 Annual Meeting of Shareholders April 18, 2019 2:00 PM - BizWire Merck (MRK), Lilly (LLY), Pfizer (PFE) Weakness Continues as Biotech Shares Get Hit Again April 18, 2019 10:23 AM - StreetInsider Merck (MRK), Pfizer (PFE) Lilly (LLY) Shares Decline Amid Biotech Weakness April 17, 2019 10:26 AM - StreetInsider Form 4 PFIZER INC For: Apr 15 Filed by: ROGERS DAWN April 16, 2019 7:20 PM - SEC Filing Form 4 PFIZER INC For: Apr 15 Filed by: YOUNG JOHN D April 16, 2019 7:19 PM - SEC Filing Form 4 PFIZER INC For: Apr 15 Filed by: BOURLA ALBERT April 16, 2019 7:18 PM - SEC Filing Form 4 PFIZER INC For: Apr 15 Filed by: JOHNSON RADY A April 16, 2019 7:18 PM - SEC Filing Pfizer (PFE) option implied volatility flat as shares near record high April 16, 2019 10:20 AM - StreetInsider Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults A April 13, 2019 4:00 AM - BizWire Form 4 PFIZER INC For: Apr 10 Filed by: YOUNG JOHN D April 11, 2019 4:07 PM - SEC Filing Form 4 PFIZER INC For: Apr 10 Filed by: BOURLA ALBERT April 11, 2019 4:07 PM - SEC Filing Form 4 PFIZER INC For: Apr 10 Filed by: JOHNSON RADY A April 11, 2019 4:06 PM - SEC Filing Form 4 PFIZER INC For: Apr 10 Filed by: ROGERS DAWN April 11, 2019 4:06 PM - SEC Filing GlaxoSmithKline (GSK) and Pfizer (PFE) announce FDA approval of ViiV Healthcare's Dovato for treatment-naïve HIV-1 adults April 8, 2019 4:54 PM - StreetInsider US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults April 8, 2019 4:49 PM - BizWire Form PX14A6G PFIZER INC Filed by: SISTERS OF ST FRANCIS OF PHILADELPHIA April 8, 2019 10:36 AM - SEC Filing Pfizer (PFE) Announces FDA Approval of IBRANCE for Treatment of Men with HR+, HER2- Metastatic Breast Cancer April 4, 2019 2:58 PM - StreetInsider U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer April 4, 2019 2:57 PM - BizWire AM Best Affirms Credit Ratings of Blue Whale Re Ltd. April 4, 2019 10:04 AM - BizWire Pfizer (PFE) option implied volatility at lower end of range April 3, 2019 11:10 AM - StreetInsider Pfizer (PFE) Announces VIZIMPRO Receives MAA in EU for First-Line Treatment of Adult Patients with EGFR-Mutated NSCLC April 3, 2019 9:43 AM - StreetInsider VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer April 3, 2019 9:42 AM - BizWire Pfizer (PFE) call put ratio 2.8 calls to 1 put April 3, 2019 5:13 AM - StreetInsider Form 4 PFIZER INC For: Mar 29 Filed by: BOURLA ALBERT April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: JOHNSON RADY A April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: ROGERS DAWN April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: YOUNG JOHN D April 2, 2019 3:07 PM - SEC Filing Form 4 PFIZER INC For: Apr 01 Filed by: MACKENZIE ALEXANDER R April 2, 2019 3:06 PM - SEC Filing Sangamo/Pfizer Data Competitive, But BioMarin (BMRN) is 'Meaningfully Ahead in Development' - Baird April 2, 2019 12:45 PM - StreetInsider Form DEFA14A PFIZER INC April 2, 2019 12:25 PM - SEC Filing Pfizer (PFE) option implied volatility at low end of range April 2, 2019 10:19 AM - StreetInsider Pre-Open Stock Movers 04/02: (ADMA) (SGMO) (RIOT) Higher; (APYX) (EFOI) (WBA) Lower (more...) April 2, 2019 9:24 AM - StreetInsider Sangamo Therapeutics (SGMO) Reports Clinical Development Update Including Early Phase 1/2 Beta Thalassemia Gene-edited Cell Therapy Data April 2, 2019 7:06 AM - StreetInsider Sangamo Therapeutics (SGMO), Pfizer (PFE) Report Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy April 2, 2019 7:01 AM - StreetInsider Sangamo and Pfizer Announce Phase 1/2 Interim Data For Investigational Hemophilia A Gene Therapy April 2, 2019 7:00 AM - PR NewsWire Sangamo and Pfizer Announce Phase 1/2 Interim Data for Investigational Hemophilia A Gene Therapy April 2, 2019 7:00 AM - BizWire Form 4 PFIZER INC For: Mar 29 Filed by: SMITH JAMES C April 1, 2019 7:01 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: KILTS JAMES M April 1, 2019 7:01 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: NARAYEN SHANTANU April 1, 2019 7:01 PM - SEC Filing Form 4 PFIZER INC For: Mar 29 Filed by: Echevarria Joseph April 1, 2019 7:01 PM - SEC Filing Bank of America Merrill Lynch Releases Top 10 US Ideas for 2Q April 1, 2019 7:56 AM - StreetInsider Pfizer (PFE) PT Raised to $48 at BofA/Merrill Lynch Ahead of Orphan Drug Catalyst April 1, 2019 6:46 AM - StreetInsider SpringWorks Therapeutics Completes $125 Million Series B Financing April 1, 2019 6:30 AM - BizWire NetworkNewsAudio – Genprex Inc. (NASDAQ: GNPX) Establishing Itself as a Trailblazer in Breakthrough Cancer Treatments March 29, 2019 9:00 AM - StreetInsider The EIU's Index of Cancer Preparedness reveals huge gaps in health system readiness and governance March 28, 2019 6:55 AM - StreetInsider Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy March 27, 2019 9:00 AM - StreetInsider S&P 500 Q4 2018 Buybacks Set 4th Consecutive Quarterly Record at $223 Billion; 2018 Sets Record $806 Billion March 25, 2019 10:53 AM - PR NewsWire Form PX14A6G PFIZER INC Filed by: Trinity Health Corp March 21, 2019 3:22 PM - SEC Filing Merck KGaA and Pfizer (PFE) Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 20, 2019 12:00 PM - StreetInsider Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 20, 2019 11:59 AM - PR NewsWire Pfizer (PFE) Buys 15% Stake and Option to Acquire Gene Therapy Company Vivet Therapeutics March 20, 2019 6:46 AM - StreetInsider Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics March 20, 2019 6:45 AM - BizWire Pfizer (PFE), Merck KGaA Report Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 20, 2019 6:09 AM - StreetInsider Merck KGaA, Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase III JAVELIN Ovarian PARP 100 Trial in Previously Untreated Advanced Ovarian Cancer March 19, 2019 7:15 PM - PR NewsWire Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts March 19, 2019 10:00 AM - BizWire Full Article List